Latest News

PBF Energy (PBF) has pulled back roughly 13% over the past month after a solid run earlier this year, and that slide is catching the attention of value oriented investors in the refining space. See our latest analysis for PBF Energy. Zooming out, that 1 month share price pullback sits against a still solid backdrop, with a roughly 19% year to date share price return and a powerful 5 year total shareholder return that suggests long term momentum has not completely faded. If volatility in...

Boston Scientific (BSX) has quietly pulled back, with shares down about 4% over the past week and roughly 13% over the past 3 months. This may offer investors a fresh entry point. See our latest analysis for Boston Scientific. Zooming out, the recent slide sits against a steadier backdrop, with the share price still modestly positive year to date and long term total shareholder returns near doubling over three years. This suggests momentum is cooling rather than collapsing. If Boston...

Mitsui Kinzoku Company (TSE:5706) has quietly turned into a serious momentum story, with the share price climbing about 75% over the past 3 months and nearly tripling investors money year to date. See our latest analysis for Mitsui Kinzoku Company. That surge has come on top of an already impressive run, with the 1 year total shareholder return near 290% and the 3 year total shareholder return above 540%. This suggests that momentum is still very much building rather than fading. If Mitsui...

Sphere Entertainment (SPHR) just pushed to a record high after its third quarter earnings, even though revenue slightly trailed forecasts and earnings per share fell short, thanks to stronger than expected adjusted operating income. See our latest analysis for Sphere Entertainment. The latest move caps a powerful run, with the share price delivering a roughly 54% 90 day return and a 1 year total shareholder return of about 128%, signaling strong positive momentum as investors re rate Sphere...

In its recently reported 2Q26 results, Doximity beat revenue and EPS estimates with about 23% year-over-year growth, while maintaining near-60% adjusted EBITDA margins and free cash flow margins above 40% on a cash-rich, low-debt balance sheet. The quarter underscored how rapidly clinicians are adopting Doximity’s AI-enabled workflow tools, which are becoming an increasingly central part of their daily practice. Next, we’ll examine how the accelerating adoption of AI-powered workflow tools...

AECOM ( NYSE:ACM ) has announced that it will be increasing its dividend from last year's comparable payment on the...

Ascendis Pharma (NasdaqGS:ASND) just told investors the FDA has tagged its latest TransCon CNP filing as a major amendment, pushing the decision deadline to February 28, 2026, and subtly reshaping expectations for potential approval. See our latest analysis for Ascendis Pharma. The update lands after a strong run, with Ascendis Pharma’s year to date share price return of around 50% and 1 year total shareholder return of about 56%. This suggests momentum is still building as investors reassess...

In recent weeks, CRISPR Therapeutics has drawn fresh attention as it advances its CRISPR-based gene-editing pipeline, including early clinical work on CTX310 for lowering LDL cholesterol and triglycerides and ongoing commercialization of its approved therapy Casgevy for blood disorders. What stands out is how early progress with CTX310, alongside revised earnings expectations and sustained institutional interest, is beginning to reshape perceptions of CRISPR Therapeutics’ long-term role in...

Berkshire Hathaway (BRK.A) has quietly slipped about 1% over the past day and 2% this week, a small move that still invites a closer look at how the long term picture stacks up. See our latest analysis for Berkshire Hathaway. That dip sits against a share price that is still up solidly year to date, while a strong multi year total shareholder return suggests long term holders have been well rewarded even as near term momentum cools. If this kind of steady compounder appeals to you, it could...

Upbound Group, Inc. recently confirmed that its Board of Directors approved a first-quarter 2026 quarterly cash dividend of US$0.39 per share, payable on January 6, 2026, to shareholders of record on December 17, 2025. This continued dividend commitment, alongside the earlier refinancing of the company’s term loan to enhance liquidity and extend its maturity, signals a focus on maintaining financial flexibility while returning cash to shareholders. We’ll now explore how the refreshed term...

Otis Worldwide’s Korean unit recently received Elevator World’s Project of the Year award for its work on Incheon International Airport’s Terminal 2 expansion, which included installing 172 elevators, escalators, and Asia’s longest continuous moving walks using a synchronized dual‑motor system. This recognition underscores Otis’s capability to deliver complex, high-throughput mobility systems for major infrastructure hubs, reinforcing its position as a preferred partner for advanced airport...

Kinder Morgan recently issued preliminary guidance for 2025 and 2026, projecting Net income attributable to the company of about US$2.90 billion and US$3.10 billion respectively, alongside an annualized 2026 dividend of US$1.19 per share that would mark its ninth consecutive yearly increase. The company’s outlook leans heavily on growing contracted LNG feedgas volumes and natural gas pipeline expansions, which together underpin fee-based earnings expectations and support its capacity to keep...

IMAX (IMAX) has been getting fresh attention after its investor day, where management laid out growth targets above what many on Wall Street were expecting, along with an expanded China partnership with Wanda Film. See our latest analysis for IMAX. The upbeat investor day and fresh content partnerships seem to be feeding into a clear trend, with an 11.66% 1 month share price return and a 163.52% 5 year total shareholder return suggesting momentum is still building rather than fading. If...

In late November and early December 2025, BeOne Medicines reported positive Phase 1/2 data for its investigational BCL2 inhibitor sonrotoclax in relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia, alongside U.S. FDA Priority Review, Breakthrough Therapy, Fast Track and multiple Orphan Drug designations, plus participation in Project Orbis. The new data, including an overall response rate of 52.4% in heavily pretreated mantle cell lymphoma and rapid, sustained...

In early December 2025, BofA Securities downgraded PROCEPT BioRobotics from Buy to Neutral, citing slower utilization growth and decelerating system sales for its Aquablation technology amid tighter hospital capital budgets. The report still emphasized PROCEPT’s sizable market opportunity and financial flexibility, highlighting a tension between near-term growth concerns and longer-term adoption potential for Aquablation in benign prostatic hyperplasia. We’ll now examine how this slowdown in...

Core & Main, Inc. has reported past third-quarter 2025 results with net sales of US$2,062 million and net income of US$137 million, alongside reaffirmed full-year guidance for net sales of US$7.60 billion to US$7.70 billion. The company also expanded its share repurchase authorization to US$1.00 billion, highlighting an increased commitment to returning capital to shareholders. Next, we’ll examine how reaffirmed guidance and the larger share repurchase plan may influence Core & Main’s...

DPM Metals Inc. recently reported its first Mineral Resource Estimates for the Dumitru Potok, Rakita North and Frasen prospects in eastern Serbia, outlining 84.4 million tonnes of inferred resources at 0.97 g/t gold and 1.02% copper, close to planned Coka Rakita infrastructure. These new resources, together with the Coka Rakita feasibility study confirming a high-margin underground mine underpinned by DPM’s long-standing Serbian presence, point to a potential district-scale gold-copper hub...

Healthpeak Properties, Inc. recently released an updated investor presentation and shifted to paying monthly dividends, while outlining plans to monetize up to US$1.00 billion of its outpatient medical office portfolio to fund development, acquisitions, and share repurchases. This combination of a clearer investor roadmap, a higher and more frequent dividend, and recycling capital from outpatient assets highlights a sharpened focus on capital allocation and income consistency for...

Alexandria Real Estate Equities (ARE) is back on investors radar following a 45% dividend cut, weak third quarter results, and a sharp share price drop that has already attracted several securities class action lawsuits. See our latest analysis for Alexandria Real Estate Equities. The latest selloff has pushed Alexandria Real Estate Equities’ share price down to about $44.97, with a steep year to date share price return of around minus 53.9% and a five year total shareholder return of roughly...

Financial momentum reshapes expectations for F&G Annuities & Life F&G Annuities & Life (FG) is back on investors radar after a powerful run in net premiums earned and an upbeat outlook for book value growth that reframes its earnings trajectory. See our latest analysis for F&G Annuities & Life. Even with the latest share price at $33.01 and a solid 1 month share price return of 7.14%, the year to date share price return of negative 19.74% and 1 year total shareholder return of negative 24.78%...

GEO Group (GEO) has been grinding through a tricky year, and the stock’s recent bounce contrasts sharply with its weak past 3 months and deep year to date drawdown. See our latest analysis for GEO Group. Over the past few weeks, a 10.91% 1 month share price return to $16.78 has only partially offset GEO Group’s sharp year to date share price loss, while its 3 year total shareholder return still looks robust, suggesting sentiment is stabilising after a tough stretch. If GEO’s rebound has you...

Arthur J. Gallagher (AJG) has been slipping lately, with the stock down over the past month and past 3 months, even as revenue and net income continue to grow at a healthy double digit clip. See our latest analysis for Arthur J. Gallagher. Zooming out, that recent weakness sits against a share price of $237.85 and a solid backdrop, with the 5 year total shareholder return of 108.16 percent still signaling long term momentum, even as shorter term share price returns cool. If AJG's pullback has...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...

As we approach the end of 2025, Canadian markets have shown strong performance with the TSX delivering double-digit gains. Amidst this backdrop, investors are closely monitoring central bank meetings and employment data while anticipating a potential Santa Claus rally. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer substantial growth opportunities when they boast solid financials and fundamentals.